Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC lifted its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 6.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 904,900 shares of the company's stock after buying an additional 53,605 shares during the quarter. Rice Hall James & Associates LLC owned approximately 1.45% of Evolus worth $14,659,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Quest Partners LLC purchased a new position in Evolus during the 2nd quarter worth $43,000. Quarry LP purchased a new position in Evolus during the 2nd quarter worth $54,000. Profund Advisors LLC purchased a new position in Evolus during the 2nd quarter worth $130,000. Arizona State Retirement System increased its holdings in Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock worth $158,000 after purchasing an additional 1,253 shares during the period. Finally, ProShare Advisors LLC increased its holdings in Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company's stock worth $162,000 after purchasing an additional 1,035 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on EOLS shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Evolus in a research report on Friday. Finally, Barclays increased their target price on Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, September 13th.

Insider Buying and Selling

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares in the company, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by insiders.

Evolus Stock Performance

Shares of NASDAQ EOLS traded up $0.43 during trading on Friday, reaching $16.75. 374,201 shares of the company traded hands, compared to its average volume of 578,875. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. Evolus, Inc. has a 12-month low of $7.67 and a 12-month high of $17.82. The firm's fifty day simple moving average is $16.23 and its 200 day simple moving average is $13.67. The stock has a market cap of $1.06 billion, a P/E ratio of -18.41 and a beta of 1.31.

Evolus (NASDAQ:EOLS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to analysts' expectations of $65.06 million. As a group, research analysts anticipate that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.